Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…Abstract Number: 1198 • 2019 ACR/ARP Annual Meeting
Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents
Background/Purpose: Immunosuppressive agents have changed the course of debilitating autoimmune conditions. Despite their advantages, these agents come with risk of vaccine preventable infections.1 Multiple organizations recommend…Abstract Number: 2124 • 2019 ACR/ARP Annual Meeting
Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?
Background/Purpose: American Trypanosomiasis or Chagas Disease (CD) is a zoonotic infection, endemic in Latin America. It is a major cause of morbidity, mortality and economic…Abstract Number: 2135 • 2019 ACR/ARP Annual Meeting
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Background/Purpose: Recently the term “interstitial pneumonia with autoimmune features” (IPAF) has been proposed to identify patients with interstitial lung disease and autoimmune characteristics, not fulfilling…Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…Abstract Number: 705 • 2018 ACR/ARHP Annual Meeting
Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose: Human papillomavirus (HPV), a common sexually-transmitted infection, is considered a necessary cause of cervical cancer. The objectives of this systematic review and meta-regression were:…Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…Abstract Number: 1249 • 2018 ACR/ARHP Annual Meeting
Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs
Background/Purpose: Women of child bearing age with autoimmune diseases are often prescribed teratogenic medications as Methotrexate, Mycophenolate Mofetil, Leflunomide and Cyclophosphamide. Contraceptive compliance in this…Abstract Number: 1289 • 2018 ACR/ARHP Annual Meeting
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
Background/Purpose: Gout is a frequent co-morbidity of solid organ transplant (SOT). Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as…Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting
Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index
Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting
Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…Abstract Number: 2669 • 2018 ACR/ARHP Annual Meeting
Assessing the Need for Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis in SLE Patients on Immunosuppression
Background/Purpose: The risk-benefit of Pneumocystis jiroveci pneumonia (PCP) prophylaxis in systemic lupus erythematosus (SLE) is not well defined and there are no SLE-specific guidelines. On…Abstract Number: 2713 • 2018 ACR/ARHP Annual Meeting
Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in SSc. Immunosuppression is used to treat ILD, but little is known about its…
- 1
- 2
- 3
- 4
- Next Page »